期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

抗肿瘤药物性血栓性微血管病肾损伤1例报道

Renal injury in thrombotic microangiopathy caused by anti-tumor agent:one case report
下载PDF
导出
摘要 病例资料患者,女,72岁,因“发现尿蛋白10 d”于2022年1月3日入院。10 d前于其他医院体检时发现尿蛋白阳性(未见化验结果),入院后检查24 h尿蛋白定量4.05 g。患者自本次患病以来,无发热、干咳,无胸闷、胸痛,偶有活动后气短,无皮疹,无光过敏,无脱发、口腔溃疡,无关节肿痛,无恶心、呕吐,无腹痛、腹泻,无肉眼血尿,自觉尿中泡沫增多,无尿频、尿急、尿痛,精神、饮食可,睡眠一般,尿量约1700 mL,大便正常,近期体重未监测。既往史:发现高血压1个月,最高180/110 mmHg(1 mmHg=0.133 kPa),目前口服“替米沙坦40 mg/d、苯磺酸左氨氯地平2.5 mg/d”,监测收缩压波动于150 mmHg左右。诊断肺部恶性肿瘤(腺癌)2年,既往行化疗(卡铂、培美曲塞),目前输注贝伐单抗(每月1次)。15年前因胆囊结石行胆囊切除术。个人史:无特殊。体格检查:体温36.3℃,脉搏84次/min,呼吸20次/min,血压150/85 mmHg。神清语利,体格检查合作,颜面无浮肿,双肺呼吸音清晰,未闻及干湿啰音,心率84次/min,律齐,腹平软,无压痛、反跳痛,肝脏未触及,脾脏未触及,双下肢不肿。
作者 胡文慧 张伟 居红格 Hu Wen-hui;Zhang Wei;Ju Hong-ge(School of Medicine,Baotou 014040,China;Department of Pathology,First Affiliated Hospital,Baotou Medical College,Baotou 014040,China)
机构地区 包头医学院 包头医学院第一附属医院病理科
出处 《临床肾脏病杂志》 2023年第3期262-264,F0003,共4页 Journal Of Clinical Nephrology
基金 包头医学院青年科技人才发展计划(BYJJ-QNGG2022012)。
关键词 贝伐单抗 抗肿瘤药物 血栓性微血管病 Bevacizumab Anti-tumor agent Thrombotic microangiopathy
分类号 R692 [医药卫生—泌尿科学]
  • 相关文献

参考文献7

二级参考文献59

  • 1Zhu X,Wu S,Dahut WL,et al.Risks of proteinuria and hypertension with bevacizumab,an antibody against vascular endothelial growth factor:systematic review and meta-analysis[J].Am J Kidney Dis,2007,49(2):186-193.
  • 2Mok TS,Hsia TC,Tsai CM,et al.Efficacy of bevacizumab with cisplatin and gemcitabine in Asian patients with ad-vanced or recurrent non-squamous non-small cell lung cancer who have not received prior chemotherapy:a substudy of the Avastin in lung trial[J].Asia Pac J Clin Oncol,2011,7(Suppl2):4-12.
  • 3Robert NJ,Die'ras V,Glaspy J,et al.RIBBON-1:random-ized,double-blind,placebo-controlled,phaseⅢtrial of chemotherapy with or without bevacizumab for first-line treat-ment of human epidermal growth factor receptor2-negative,locally recurrent or metastatic breast cancer[J].J Clin On-col,2011,29(10):1252-1260.
  • 4Leighl NB,Zatloukal P,Mezger J,et al.Efficacy and safe-ty of bevacizumab-base therapy in elderly patients with ad-vanced or recurrent non-squamous non-small cell lung cancer in the phaseⅢBO17704study(AVAiL)[J].J Thorac Oncol,2010,5(12):1970-1976.
  • 5Stathopoulos GP,Batziou C,Trafalis D,et al.Treatment of colorectal cancer with and without bevacizumab:a phaseⅢstudy[J].Oncology,2010,78(5-6):376-381.
  • 6Kindler HL,Niedzwiecki D,Hollis D,et al.Gemcitabineplus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer:phaseⅢtrial of the cancer and Leukemia Group B(CALGB80303)[J].J Clin Oncol,2010,28(22):3617-3622.
  • 7Tebbutt NC,Wilson K,Gebski VJ,et al.Capecitabine,bevacizumab and mitomycin in first-line treatment of meta-static colorectal cancer:results of the Australasian gastroin-testinal trials group randomized,phaseⅢMAX study[J].J Clin Oncol,2010,28(19):3191-3198.
  • 8Miles DW,Chan A,Dirix LY,et al.PhaseⅢstudy of bev-acizumab plus decetaxel compared with placebo plus do-cetaxel for the first-line treatment of human epidermal growth factor receptor-2negative metastatic breast cancer[J].J Clin Oncol,2010,28(20):3239-3247.
  • 9Allegra CJ,Yothers G,O'Connell MJ,et al.Initial safety report of NSABP C-08:a randomized phaseⅢstudy of mod-ified FOLFOX6with or without bevacizumab for the adjuvant treatment of patients with stageⅡorⅢcolon cancer[J].J Clin Oncol,2009,27(20):3385-3390.
  • 10Sobrero A,Ackland S,Clarke S,et al.PhaseⅣstudy of bevacizumab in combination with infusional fluorouracil,leu-covorin and irinotecan(FOLFIRI)in first-line metastatic colorectal cancer[J].Oncology,2009,77(2):113-119.

共引文献29

临床肾脏病杂志
2023年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部